{"id":"W4389329605","doi":"10.1182/bloodadvances.2023011721","title":"Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; Ludwig Center at Harvard; Sierra Oncology; Astellas Pharma; U.S. Department of Defense; Gilead Sciences; Genentech; Bristol-Myers Squibb; AstraZeneca; Servier; Pfizer","keywords":"Azacitidine; Medicine; Venetoclax; Internal medicine; Hypomethylating agent; Myeloid leukemia; Adverse effect; Interleukin-3 receptor; Minimal residual disease; Leukemia; Decitabine; Myelodysplastic syndromes; Oncology; Gastroenterology; Immunology; Chronic lymphocytic leukemia; Bone marrow; Biology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008846186,0.001249882,0.001581636,0.0003210779,0.0003562282,0.0007388622,0.0005581795,0.0009477482,0.002779069],"category_scores_gemma":[0.0004979242,0.0003869319,0.0006704665,0.0002685901,0.000738068,0.0005525379,0.0002928662,0.002548266,0.000746339],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006501005,"about_ca_system_score_gemma":0.0008350179,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000724397,"about_ca_topic_score_gemma":0.001306737,"domain_scores_codex":[0.9997486,0.0001101328,0.00001056468,0.00005240503,0.00001938225,0.00005874842],"domain_scores_gemma":[0.9996485,0.00005866359,0.00005096879,0.00004015026,0.00001683864,0.0001849452],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6508007,0.09443186,0.007845645,0.0008409874,0.001137731,0.000596129,0.0005254813,0.003507187,0.1082037,0.0005822314,0.005134258,0.1263941],"study_design_scores_gemma":[0.363041,0.6087983,0.01382111,0.00003939012,0.000271582,0.0005201785,0.00005899065,0.001106273,0.008641729,0.0002097078,0.003464913,0.00002662246],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954379,0.001435256,0.0003313755,0.000237036,0.00008370267,0.0009060465,0.0005628782,0.00006713357,0.0009386032],"genre_scores_gemma":[0.9922968,0.001125295,0.0008824469,0.0004039004,0.0001094954,0.00111148,0.001795541,0.0000230758,0.002251901],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002779069,"threshold_uncertainty_score":0.009296894,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02240965027802033,"score_gpt":0.3371219432877385,"score_spread":0.3147122930097182,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}